tbuckley/cabot-search huggingface dataset:
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Authors: Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero
Journal: New England Journal of Medicine (2023)

In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest that treatment with FTD-TPI in addition to bevacizumab has the potential to extend survival.We randomly assigned, in a 1:1 ratio, adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer to receive FTD-TPI plus bevacizumab (combination group) or FTD-TPI alone (FTD-TPI group). The primary end point was overall survival. Secondary end points were progression-free survival and safety, including the time to worsening of the Eastern Cooperative Oncology Group (ECOG) performance-status score from 0 or 1 to 2 or more (on a scale from 0 to 5, with higher scores indicating greater disability).A total of 246 patients were assigned to each group. The median overall survival was 10.8 months in the combination group and 7.5 months in the FTD-TPI group (hazard ratio for death, 0.61; 95% confidence interval [CI], 0.49 to 0.77; P<0.001). The median progression-free survival was 5.6 months in the combination group and 2.4 months in the FTD-TPI group (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.54; P<0.001). The most common adverse events in both groups were neutropenia, nausea, and anemia. No treatment-related deaths were reported. The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67).Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.).
Intravenous Contrast in Computed Tomography Imaging for Acute Abdominal Pain
Authors: D. Dante Yeh, Courtney C. Moreno, Mayur B. Patel
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Genomic Evidence for the Nonpathogenic State in HIV-1–Infected Northern Pig-Tailed Macaques
Authors: Wei Pang, Yong Shao, Xiao-Lin Zhuang, Ying Lu, Wen-Qiang He, Hong-Yi Zheng, Rong Xin, Ming-Xu Zhang, Xiao-Liang Zhang, Jia-Hao Song, Ren-Rong Tian, Fan Shen, Yi-Hui Li, Zu-Jiang Zhao, Dong-Dong Wu, Yong-Tang Zheng
Journal: Molecular Biology and Evolution (2023)

HIV-1 is a highly host-specific retrovirus that infects humans but not most nonhuman primates. Thus, the lack of a suitable primate model that can be directly infected with HIV-1 hinders HIV-1/AIDS research. In the previous study, we have found that the northern pig-tailed macaques (NPMs) are susceptible to HIV-1 infection but show a nonpathogenic state. In this study, to understand this macaque-HIV-1 interaction, we assembled a de novo genome and longitudinal transcriptome for this species during the course of HIV-1 infection. Using comparative genomic analysis, a positively selected gene, Toll-like receptor 8, was identified with a weak ability to induce an inflammatory response in this macaque. In addition, an interferon-stimulated gene, interferon alpha inducible protein 27, was upregulated in acute HIV-1 infection and acquired an enhanced ability to inhibit HIV-1 replication compared with its human ortholog. These findings coincide with the observation of persistently downregulated immune activation and low viral replication and can partially explain the AIDS-free state in this macaque following HIV-1 infection. This study identified a number of unexplored host genes that may hamper HIV-1 replication and pathogenicity in NPMs and provided new insights into the host defense mechanisms in cross-species infection of HIV-1. This work will facilitate the adoption of NPM as a feasible animal model for HIV-1/AIDS research.
Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study
Authors: Xiangli Fan, Jing Wang, Lingling Xia, Hu Qiu, Yuanyuan Tian, Yutian Zhangcai, Xixi Luo, Yuelan Gao, Chen Li, Yong Wu, Wensi Zhao, Jiamei Chen, Wei Shi, Jingping Yuan, Shaobo Ke, Yongshun Chen
Journal: International Journal of Surgery (2023)

The efficacy of endoscopic therapy on the long-term survival outcomes of T1b oesophageal cancer (EC) is unclear, this study was designed to clarify the survival outcomes of endoscopic therapy and to construct a model for predicting the prognosis in T1b EC patients.
Commentary on ‘Effectiveness of artificial intelligence-assisted colonoscopy in early diagnosis of colorectal cancer: a systematic review’
Authors: Yi Zhang, Yujiang Li, Yun Qian, Zhou Wang
Journal: International Journal of Surgery (2023)

aDepartment of Gastroenterology, Taizhou People's Hospital, Jiangsu, 225300, China bDepartment of Emergency, Taizhou People's Hospital, Jiangsu, 225300, China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: CHINA. E-mail address: [email protected] (Z. Wang). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Outbreak of Cosmetology-Acquired <i>Mycobacterium abscessus</i> Skin Infection
Authors: Yuansu Jiang, Xia Lei, Weiping Lu
Journal: JAMA Dermatology (2023)

This case report describes numerous warm, red, edematous, tender, fluctuant, and purulent draining nodules on the abdomen following a catgut implant procedure.
Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides During Rituximab Maintenance Therapy
Authors: Nihel Khoudour, Florence Delestre, Fabienne Jabot‐Hanin, Anne Jouinot, Juliette Nectoux, Franck Letouneur, Brigitte Izac, Michel Vidal, Loïc Guillevin, Xavier Puéchal, Pierre Charles, Benjamin Terrier, Benoit Blanchet
Journal: Arthritis & Rheumatology (2023)

Interindividual variability in response to rituximab remains unexplored in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rituximab pharmacokinetics (PK) and pharmacodynamics (PD) as well as genetic polymorphisms could contribute to variability. This ancillary study of the MAINRITSAN 2 trial aimed to explore the relationship between rituximab plasma concentration, genetic polymorphisms in PK/PD candidate genes, and clinical outcomes.Patients included in the MAINRITSAN2 trial (ClinicalTrials.gov identifier: NCT01731561) were randomized to receive a 500-mg fixed-schedule rituximab infusion or an individually tailored regimen. Rituximab plasma concentrations at month 3 (CM3) were assessed. DNA samples (n = 53) were genotyped for single-nucleotide polymorphisms within 88 putative PK/PD candidate genes. The relationship between PK/PD outcomes and genetic variants was investigated using logistic linear regression in additive and recessive genetic models.One hundred and thirty-five patients were included. The frequency of underexposed patients (<4 μg/ml) in the fixed-schedule group was statistically lower compared to that in the tailored-infusion group (2.0% versus 18.0%; P = 0.02, respectively). Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml) was an independent risk factor for major relapse (odds ratio 6.56 [95% confidence interval (95% CI) 1.26-34.09]; P = 0.025) at month 28 (M28). A sensitivity survival analysis also identified CM3 <4 μg/ml as an independent risk factor for major relapse (hazard ratio [HR] 4.81 [95% CI 1.56-14.82]; P = 0.006) and relapse (HR 2.70 [95% CI 1.02-7.15]; P = 0.046). STAT4 rs2278940 and PRKCA rs8076312 were significantly associated with CM3 but not with major relapse onset at M28.These results suggest that drug monitoring could be useful to individualize the schedule of rituximab administration within the maintenance phase.
Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder
Authors: Eline B. Rognli, Ina H. Heiberg, Bjarne K. Jacobsen, Anne Høye, Jørgen G. Bramness
Journal: American Journal of Psychiatry (2023)

Objective: The authors investigated transitions to schizophrenia spectrum or bipolar disorder following different types of substance-induced psychosis and the impact of gender, age, number of emergency admissions related to substance-induced psychosis, and type of substance-induced psychosis on such transitions. Methods: All patients in the Norwegian Patient Registry with a diagnosis of substance-induced psychosis from 2010 to 2015 were included (N=3,187). The Kaplan-Meier method was used to estimate cumulative transition rates from substance-induced psychosis to either schizophrenia spectrum disorder or bipolar disorder. Cox proportional hazard regression was used to estimate hazard ratios for transitions to schizophrenia spectrum or bipolar disorders associated with gender, age, number of emergency admissions, and type of substance-induced psychosis. Results: The 6-year cumulative transition rate from substance-induced psychosis to schizophrenia spectrum disorder was 27.6% (95% CI=25.6–29.7). For men, the risk of transition was higher among younger individuals and those with either cannabis-induced psychosis or psychosis induced by multiple substances; for both genders, the risk of transition was higher among those with repeated emergency admissions related to substance-induced psychosis. The cumulative transition rate from substance-induced psychosis to bipolar disorder was 4.5% (95% CI=3.6–5.5), and the risk of this transition was higher for women than for men. Conclusions: Transition rates from substance-induced psychosis to schizophrenia spectrum disorder were six times higher than transition rates to bipolar disorder. Gender, age, number of emergency admissions, and type of substance-induced psychosis affected the risk of transition.
On children’s visits, mobile phones and family empowerment in paediatric intensive care medicine. Author’s reply
Authors: Maria Brauchle, Teresa Deffner, Peter Nydahl, Alexander Brinkmann, Svenja Dehner, Rolf Dubb, Simon Finkeldei, Birga Gatzweiler, Carsten Hermes, Christian Heyd, Magdalena Hoffmann, Marie-Madlen Jeitziner, Arnold Kaltwasser, Tita Kern, Kathrin Knochel, Lars Krüger, Heiner Melching, Guido Michels, Tilmann Müller-Wolff, Sabrina Pelz, Julian Rudolph, Denise Schindele, Anna-Henrikje Seidlein, Arne Simon, Marina Ufelmann
Journal: Intensive Care Medicine (2023)

The authors acknowledged the publication and added two more recommendations nr.11 and 12 and shared one observation.The first recommendation includes the facilitation of "mobile phones for taking pictures and/or making audio recordings and film footage of loved ones in the intensive care unit (ICU)", the second recommendation includes "online visiting and making contact" via apps for video conferencing.Finally, they are questioning the implementation feasibility in real-life critical care, requiring specialized staff, and observed that all recommendations support the "Empowerment of Families" and contribute to the ABC-DEF bundle for family-centered care.We appreciate the recommendations 11 and 12. Especially in times of visitor regulations due to isolation requirements, it is essential to offer alternatives for communication to patients and families including children.During the coronavirus disease 2019 (COVID-19) pandemic, virtual visits have been introduced on many ICUs, and a lot of clinicians and families became used to virtual visits [3].Most patients appreciated the virtual visits, and staff valued this as quality-increasing compromise due to isolation regulations.Video visits with critical care patients is also useful in case families cannot be present due to long distances, own illness, or other
Errors From Incorrect Use of Subscale
Authors: John C. Fortney
Journal: JAMA Psychiatry (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Bibliometric analysis of academic journal recommendations and requirements for surgical and anesthesiologic adverse events reporting
Authors: Tamir N. Sholklapper, Jorge Ballon, Aref S. Sayegh, Anibal La Riva, Laura C. Perez, Sherry Huang, Michael Eppler, Gregg Nelson, Giovanni Marchegiani, Robert Hinchliffe, Luca Gordini, Marc Furrer, Michael J. Brenner, Salome Dell-Kuster, Chandra Shekhar Biyani, Nader Francis, Haytham M.A. Kaafarani, Matthias Siepe, Des Winter, Julie A. Sosa, Francesco Bandello, Robert Siemens, Jochen Walz, Alberto Briganti, Christian Gratzke, Andre L. Abreu, Mihir M. Desai, Rene Sotelo, Riaz Agha, Keith D. Lillemoe, Steven Wexner, Gary S. Collins, Inderbir Gill, Giovanni E. Cacciamani
Journal: International Journal of Surgery (2023)

Background: Standards for reporting surgical adverse events (AEs) vary widely within the scientific literature. Failure to adequately capture AEs hinders efforts to measure the safety of healthcare delivery and improve the quality of care. The aim of the present study is to assess the prevalence and typology of perioperative AE reporting guidelines among surgery and anesthesiology journals. Materials and methods: In November 2021, three independent reviewers queried journal lists from the SCImago Journal &amp; Country Rank (SJR) portal (www.scimagojr.com), a bibliometric indicator database for surgery and anesthesiology academic journals. Journal characteristics were summarized using SCImago, a bibliometric indicator database extracted from Scopus journal data. Quartile 1 (Q1) was considered the top quartile and Q4 bottom quartile based on the journal impact factor. Journal author guidelines were collected to determine whether AE reporting recommendations were included and, if so, the preferred reporting procedures. Results: Of 1409 journals queried, 655 (46.5%) recommended surgical AE reporting. Journals most likely to recommend AE reporting were: by category surgery (59.1%), urology (53.3%), and anesthesia (52.3%); in top SJR quartiles (i.e. more influential); by region, based in Western Europe (49.8%), North America (49.3%), and the Middle East (48.3%). Conclusions: Surgery and anesthesiology journals do not consistently require or provide recommendations on perioperative AE reporting. Journal guidelines regarding AE reporting should be standardized and are needed to improve the quality of surgical AE reporting with the ultimate goal of improving patient morbidity and mortality.
Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study
Authors: Si-Yu Wu, Jian-Wei Li, Yu-Jie Wang, Kai-Rui Jin, Ben-Long Yang, Jun-Jie Li, Xiao-Li Yu, Miao Mo, Na Hu, Zhi-Ming Shao, Guang-Yu Liu
Journal: International Journal of Surgery (2023)

Targeted axillary dissection (TAD) includes biopsy of clipped lymph node and sentinel lymph nodes. However, clinical evidence regarding clinical feasibility and oncological safety of non-radioactive TAD in a real-world cohort remains limited.In this prospective registry study, patients routinely underwent clip insertion into biopsy-confirmed lymph node. Eligible patients received neoadjuvant chemotherapy followed by axillary surgery. Main endpoints included the false-negative rate (FNR) of TAD and nodal recurrence rate.Data from 353 eligible patients were analyzed. After completion of neoadjuvant chemotherapy, 85 patients directly proceeded to axillary lymph node dissection (ALND), furthermore, TAD with or without ALND was performed in 152 and 85 patients, respectively. Overall detection rate of clipped node was 94.9% (95% CI, 91.3-97.4%) and FNR of TAD was 12.2% (95% CI, 6.0-21.3%) in our study, with FNR decreasing to 6.0% (95% CI, 1.7-14.6%) in initially cN1 patients. During a median follow-up of 36.6 months, 3 nodal recurrences occurred (3/237 with ALND; 0/85 with TAD alone), with a 3-year freedom-from-nodal-recurrence rate of 100.0% among the TAD-only patients and 98.7% among the ALND patients with axillary pathologic complete response ( P =0.29).TAD is feasible in initially cN1 breast cancer patients with biopsy-confirmed nodal metastases. ALND can safely be foregone in patients with negativity or a low volume of nodal positivity on TAD, with a low nodal failure rate and no compromise of 3-year recurrence-free survival.
Errors in Figure 3
Authors: Thomas O'keefe, Anne Wallace, Thomas O', Rita Mukhtar, Christina Yau, Laura Esserman
Journal: JAMA Surgery (2023)

Although treating pCR as a binary variable defined only by residual invasive disease is appealing from the standpoint of simplicity for planning analyses for future studies and for the purposes of clinical management, we feel that the reported findings do not support this.The results suggest that pCR with residual in situ disease may have prognostic utility and that this outcome should be included as an independent end point for efficacy of neoadjuvant regimens, representing an inferior response to pCR with the absence of DCIS but a superior response compared with the absence of pCR.The authors note that pCR is considered an end point for accelerated drug approval in neoadjuvant trials.The maintenance of a status of pCR with DCIS would allow for further stratification of the associations of novel agents with outcomes and possibly allow for the establishment of differential effects by breast cancer subtype.
Methods, Complications, and Outcomes in a Randomized Clinical Trial of Electroacupuncture After Colorectal Cancer Surgery
Authors: Tao Yuan, Qin Ma, Ming-Ming Zhang
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases
Authors: Samir K. Beura, Rishika Dhapola, Abhishek R. Panigrahi, Pooja Yadav, Reetesh Kumar, Dibbanti H. Reddy, Sunil K. Singh
Journal: Medicinal Research Reviews (2023)

Abstract The blood platelet plays an important role but often remains under‐recognized in several vascular complications and associated diseases. Surprisingly, platelet hyperactivity and hyperaggregability have often been considered the critical risk factors for developing vascular dysfunctions in several neurodegenerative diseases (NDDs) like Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. In addition, platelet structural and functional impairments promote prothrombotic and proinflammatory environment that can aggravate the progression of several NDDs. These findings provide the rationale for using antiplatelet agents not only to prevent morbidity but also to reduce mortality caused by NDDs. Therefore, we thoroughly review the evidence supporting the potential pleiotropic effects of several novel classes of synthetic antiplatelet drugs, that is, cyclooxygenase inhibitors, adenosine diphosphate receptor antagonists, protease‐activated receptor blockers, and glycoprotein IIb/IIIa receptor inhibitors in NDDs. Apart from this, the review also emphasizes the recent developments of selected natural antiplatelet phytochemicals belonging to key classes of plant‐based bioactive compounds, including polyphenols, alkaloids, terpenoids, and flavonoids as potential therapeutic candidates in NDDs. We believe that the broad analysis of contemporary strategies and specific approaches for plausible therapeutic treatment for NDDs presented in this review could be helpful for further successful research in this area.